Nov 20, 2009 By:Angie Drakulich
The international pharmaceutical supply-chain consortium Rx-360 has launched in Europe; with more than 135 industry and regulatory representatives attending to discuss the global impact of counterfeit drug products.
 |
Nov 19, 2009 By:Angie Drakulich
The international pharmaceutical supply-chain consortium Rx-360 held a launch meeting in Europe last week with more than 135 industry and regulatory representatives in attendance.
 |
Nov 6, 2009 By:Angie Drakulich
Novartis (Switzerland) plans to invest $1 billion during the next 5 years to increase R&D activities in China, including a significant expansion of The Novartis Institute of BioMedical Research (CNIBR) in Shanghai.
 |
Nov 6, 2009 By:Angie Drakulich
The International Conference on Harmonization (ICH) has adopted pharmacopeial text annexes after a meeting of the steering committee and expert working groups last week.
 |
Nov 5, 2009 By:Angie Drakulich
Last week, the steering committee and expert working groups of the International Conference on Harmonization (ICH) met in St. Louis, Missouri. A major success of the meeting was the adoption of several annexes to ICH Q4B on pharmacopeial texts.
 |
Nov 5, 2009 By:Angie Drakulich
Novartis (Basel, Switzerland) plans to invest $1 billion over the next five years to increase research and development activities in China, including a significant expansion of The Novartis Institute of BioMedical Research (CNIBR) in Shanghai.
 |
 | A panel of industry and regulatory experts, including FDA, discuss efforts to secure the global pharmaceutical supply chain. This article contains bonus online-exclusive material. Nov 2, 2009 By:Angie Drakulich
A panel of industry and regulatory experts, including FDA, discuss efforts to secure the global pharmaceutical supply chain. This article contains bonus online-exclusive material.
 |
FDA's Edwin Rivera-Martinez on dodging supply-chain challenges. Nov 2, 2009 By:Angie Drakulich
FDA's Edwin Rivera-Martinez on dodging supply-chain challenges.
 |
Oct 30, 2009 By:Angie Drakulich
The FDA needs to enhance its oversight of drugs approved on the basis of surrogate endpoints, according to a report from the Government Accountability Office (GAO).
 |
|